Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators

Abstract

This invention provides compounds of the formula (I) and (II):or the pharmaceutically acceptable esters thereof, and the pharmaceutically acceptable salts thereof: wherein Ris hydrogen or halo; Rand Rare independently hydrogen or Calkyl; Rand Rare independently hydrogen or Calkyl; Ris hydrogen, Calkyl, Calkoxy (C)alkyl or Calkyl substituted by up to 3 substituents selected from the groups consisting of Ccycloalkyl, aryl, heteroaryl and heterocyclic; Rand Rare hydrogen or taken together may form alkylene chain having one or two carbon atoms; Ris Calkyl or Ccycloalkyl; Ris Calkyl or NRR; L is (CRR)or NR; M is NRor (CRR); Rand Rare independently hydrogen or Calkyl; n is an integer from 0 to 5; and m is an integer from 0 to 2; said heterocyclic, aryl and heteroaryl are unsubstituted or are substituted by at least one substituent selected from the group consisting of halo and Calkyl; with the proviso that when Ris Calkyl, L is not NR. These compounds have 5-HTreceptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.